Personalized Functional Profiling

The Luxembourg Institute of Health (LIH) has developed a comprehensive approach to Personalized Functional Profiling (PFP) technology, this technology entails direct analysis of ex vivo tumor spheroid growth from patient biopsies in response to a curated drug panel, coupled with genomic and transcriptomic analysis of patient-derived samples. Drug screening results can typically be conveyed to the clinic within a short timeframe.
Glioblastoma, specifically recurrent glioblastoma is a particularly challenging cancer indication with limited treatment options. LIH collaborates with Luxembourg hospital partners such as CHL on the PFP project. However, the limited number of patient samples accessible hinders further optimization of PFP in GBM the context. Consequently, the project is currently focused on optimizing GBM-derived organoids for PFP with the support of the Medical Faculty Mannheim.